CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to identify genetic biomarkers to personalize epilepsy treatment and improve patient outcomes. By analyzing genome data, it aims to enhance the effectiveness of existing medications and discover new therapeutic targets.
The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted.
Epilepsy is affects 50,000,000 people of all ages worldwide.
Epilepsy is serious, increasing morbidity across all aspects of life, including a high risk of premature mortality. O…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Bruxelles / Brussel
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Genova
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Germany, Tuebingen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Heemstede
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
